

William C Weldon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/298780/publications.pdf>

Version: 2024-02-01

52
papers

1,216
citations

393982

19
h-index

395343

33
g-index

53
all docs

53
docs citations

53
times ranked

1272
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in The Gambia. <i>The Lancet Global Health</i> , 2022, 10, e257-e268. | 2.9 | 9 |
| 2 | Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. <i>Lancet</i> , The, 2021, 397, 39-50. | 6.3 | 49 |
| 3 | Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 559-568. | 4.6 | 22 |
| 4 | A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania. <i>Journal of Infectious Diseases</i> , 2021, 223, 119-127. | 1.9 | 14 |
| 5 | Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. <i>Lancet</i> , The, 2021, 397, 27-38. | 6.3 | 53 |
| 6 | Neutralizing Ljungan virus antibodies in children with newly diagnosed type 1 diabetes. <i>Journal of General Virology</i> , 2021, 102, . | 1.3 | 3 |
| 7 | Estimating population immunity to poliovirus in Jordan's high-risk areas. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 548-553. | 1.4 | 3 |
| 8 | Neutralization capacity of highly divergent type 2 vaccine-derived polioviruses from immunodeficient patients. <i>Vaccine</i> , 2020, 38, 3042-3049. | 1.7 | 8 |
| 9 | Cytokine biomarkers associated with clinical cases of acute flaccid myelitis. <i>Journal of Clinical Virology</i> , 2020, 131, 104591. | 1.6 | 4 |
| 10 | Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children. <i>Journal of Infectious Diseases</i> , 2020, , . | 1.9 | 1 |
| 11 | Immunity and field efficacy of type 2-containing polio vaccines after cessation of trivalent oral polio vaccine: A population-based serological study in Pakistan. <i>Vaccine: X</i> , 2020, 5, 100067. | 0.9 | 3 |
| 12 | Estimating population immunity to poliovirus in Lebanon: Results from a seroprevalence survey, 2016. <i>Vaccine</i> , 2020, 38, 4846-4852. | 1.7 | 0 |
| 13 | Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine. <i>Vaccine</i> , 2020, 38, 1652-1660. | 1.7 | 20 |
| 14 | Antifungal Triazole Posaconazole Targets an Early Stage of the Parechovirus A3 Life Cycle. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, . | 1.4 | 7 |
| 15 | Assessment of immunity to polio among Rohingya children in Cox's Bazar, Bangladesh, 2018: A cross-sectional survey. <i>PLoS Medicine</i> , 2020, 17, e1003070. | 3.9 | 4 |
| 16 | The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. <i>Lancet</i> , The, 2019, 394, 148-158. | 6.3 | 123 |
| 17 | Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial. <i>Lancet</i> , The, 2019, 393, 2624-2634. | 6.3 | 30 |
| 18 | Poliovirus immunity among children under five years-old in accessible areas of Afghanistan, 2013. <i>Vaccine</i> , 2019, 37, 1577-1583. | 1.7 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Rapid Disappearance of Poliovirus Type 2 (PV2) Immunity in Young Children Following Withdrawal of Oral PV2-Containing Vaccine in Vietnam. <i>Journal of Infectious Diseases</i> , 2019, 220, 386-391. | 1.9 | 10 |
| 20 | Neutralizing Antibody against Enterovirus D68 in Children and Adults before 2014 Outbreak, Kansas City, Missouri, USA1. <i>Emerging Infectious Diseases</i> , 2019, 25, 585-588. | 2.0 | 39 |
| 21 | Poliovirus Type 2 Seroprevalence Following Full- or Fractional-Dose Inactivated Poliovirus Vaccine in the Period After Sabin Type 2 Withdrawal in Sri Lanka. <i>Journal of Infectious Diseases</i> , 2019, 219, 1887-1892. | 1.9 | 7 |
| 22 | Lack of immune interference between inactivated polio vaccine and inactivated rotavirus vaccine co-administered by intramuscular injection in two animal species. <i>Vaccine</i> , 2019, 37, 698-704. | 1.7 | 8 |
| 23 | Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan. <i>Vaccine</i> , 2018, 36, 1766-1771. | 1.7 | 10 |
| 24 | Assessment of poliovirus antibody seroprevalence in polio high risk areas of West Africa. <i>Vaccine</i> , 2018, 36, 1027-1031. | 1.7 | 6 |
| 25 | Immunogenicity of Different Routine Poliovirus Vaccination Schedules: A Randomized, Controlled Trial in Karachi, Pakistan. <i>Journal of Infectious Diseases</i> , 2018, 217, 443-450. | 1.9 | 30 |
| 26 | Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine. <i>Journal of Infectious Diseases</i> , 2018, 217, 371-380. | 1.9 | 32 |
| 27 | Assessment of poliovirus antibody seroprevalence in high risk areas for vaccine derived poliovirus transmission in Madagascar. <i>Heliyon</i> , 2018, 4, e00563. | 1.4 | 6 |
| 28 | Assessing the potency and immunogenicity of inactivated poliovirus vaccine after exposure to freezing temperatures. <i>Biologicals</i> , 2018, 53, 30-38. | 0.5 | 13 |
| 29 | Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017. <i>Vaccine</i> , 2018, 36, 1921-1924. | 1.7 | 7 |
| 30 | Antifungal azoles itraconazole and posaconazole exhibit potent in vitro antiviral activity against clinical isolates of parechovirus A3 (Picornaviridae). <i>Antiviral Research</i> , 2018, 149, 75-77. | 1.9 | 21 |
| 31 | Trends in Poliovirus Seroprevalence in Kano State, Northern Nigeria. <i>Clinical Infectious Diseases</i> , 2018, 67, S103-S109. | 2.9 | 2 |
| 32 | Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants. <i>Clinical Infectious Diseases</i> , 2018, 67, S42-S50. | 2.9 | 12 |
| 33 | Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses. <i>Clinical Infectious Diseases</i> , 2018, 67, S66-S77. | 2.9 | 9 |
| 34 | Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine. <i>Journal of Infectious Diseases</i> , 2018, 218, 1876-1882. | 1.9 | 21 |
| 35 | Seroprevalence of poliovirus antibodies in the Kansas City metropolitan area, 2012-2013. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 776-783. | 1.4 | 7 |
| 36 | Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan. <i>Vaccine</i> , 2017, 35, 3209-3214. | 1.7 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses. <i>Scientific Reports</i> , 2017, 7, 12644. | 1.6 | 36 |
| 38 | Seroprevalence of Anti-polio Antibodies in Children From Polio High-risk Areas of Pakistan. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, e230-e236. | 1.1 | 6 |
| 39 | Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules. <i>Vaccine</i> , 2017, 35, 7283-7291. | 1.7 | 11 |
| 40 | Polio immunity and the impact of mass immunization campaigns in the Democratic Republic of the Congo. <i>Vaccine</i> , 2017, 35, 5693-5699. | 1.7 | 15 |
| 41 | Survey of poliovirus antibodies in Borno and Yobe States, North-Eastern Nigeria. <i>PLoS ONE</i> , 2017, 12, e0185284. | 1.1 | 3 |
| 42 | Cold chain and virus-free chloroplast-made booster vaccine to confer immunity against different poliovirus serotypes. <i>Plant Biotechnology Journal</i> , 2016, 14, 2190-2200. | 4.1 | 69 |
| 43 | The effect of diarrheal disease on bivalent oral polio vaccine (bOPV) immune response in infants in Nepal. <i>Vaccine</i> , 2016, 34, 2519-2526. | 1.7 | 11 |
| 44 | Standardized Methods for Detection of Poliovirus Antibodies. <i>Methods in Molecular Biology</i> , 2016, 1387, 145-176. | 0.4 | 97 |
| 45 | Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses. <i>Scientific Reports</i> , 2016, 6, 22094. | 1.6 | 41 |
| 46 | Seroprevalence of Poliovirus Antibodies in the United States Population, 2009–2010. <i>BMC Public Health</i> , 2016, 16, 721. | 1.2 | 16 |
| 47 | Effect of booster doses of poliovirus vaccine in previously vaccinated children, <i>Clinical Trial Results 2013</i> . <i>Vaccine</i> , 2016, 34, 3803-3809. | 1.7 | 7 |
| 48 | Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 898-904. | 4.6 | 23 |
| 49 | Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque. <i>Vaccine</i> , 2015, 33, 4683-4690. | 1.7 | 98 |
| 50 | The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. <i>Vaccine</i> , 2015, 33, 1909-1915. | 1.7 | 69 |
| 51 | Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3611-3621. | 1.4 | 41 |
| 52 | Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. <i>Vaccine</i> , 2014, 32, 4938-4944. | 1.7 | 38 |